Short-term Study Results on Arsenic Trioxide Treatment for High-risk Neuroblastoma in Children
Overview
A clinical study was conducted to assess the effectiveness and safety of arsenic trioxide (ATO) in combination with a modified N7 induction regimen for children with high-risk neuroblastoma (NB).
Key Findings
- 93% of patients achieved objective remission, with a 94% disease control rate.
- Common adverse reactions included myelosuppression (90%), gastrointestinal symptoms (49%), infections (30%), hepatotoxicity (6%), and cardiovascular toxicity (2%).
- No chemotherapy-related deaths were reported.
Practical Solutions and Value
The combination of ATO and N7-modified regimen showed superior efficacy and safety, highlighting its potential for wider clinical application.
Importance of Clinical Trials
Clinical trials play a vital role in developing safe and effective treatments. Extending their benefits to everyday medical practice is crucial for improving patient outcomes.
DocSym AI-driven Platform
Our platform, DocSym, integrates ICD-11 standards, clinical protocols, and research data into a user-friendly knowledge base, supporting clinicians in delivering quality care.
Streamlining Healthcare Operations
Efficient operations are essential in today’s healthcare landscape. Our mobile apps aid in scheduling, treatment monitoring, and telemedicine, facilitating better patient management and digital service expansion.
AI Technology for Enhanced Workflows
AI tools can optimize clinic workflows, enhance patient outcomes, and reduce paperwork burdens. Discover how we can support your practice at aidevmd.com.
